Skip to main content
. 2020 Mar 17;43(3):222–227. doi: 10.14348/molcells.2020.0051

Fig. 1. Discovery of vilazodone as an IPMK inhibitor.

Fig. 1

(A) IP metabolic pathway. (B) In silico virtual screening workflow. (C) Structure of vilazodone. (D-F) Predicted binding modes: docking scores are indicated in parentheses, respectively. The docking poses of vilazodone (D), ATP (E), and quercetin (F) within the ATP-binding core of human IPMK.